The National Medical Products Administration approved the codeine phosphate of Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Group Industrial, into China's listing of chemical raw materials, according to a Shanghai Stock Exchange filing on Friday.
The drug can be used to treat severe and frequent dry coughs, the pharmaceutical company said.
The company invested 4.6 million yuan into the research and development of the drug, the filing said.
The company's shares rose more than 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.